

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701-3271

WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

December 22, 2003

CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD/ Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

December 22, 2003

Date

Steven L. Highlander

MS DD

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/648,978 entitled "ACTIVATION OF LYMPHOCYTE POPULATIONS EXPRESSING NKG2D USING ANTI-NKG2D ANTIBODIES AND LIGAND DERIVATIVES" – Thomas Spies and Veronika Spies*
Our reference: FHCC:010US

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references B1-B2 and C1-C22.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/FHCC:010US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642

SLH/kmv

Encl.: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Thomas Spies
Veronika Spies

Serial No.: 10/648,978

Filed: August 27, 2003

For: ACTIVATION OF LYMPHOCYTE
POPULATIONS EXPRESSING NKG2D
USING ANTI-NKG2D ANTIBODIES
AND LIGAND DERIVATIVES

Group Art Unit: 1644

Examiner: Unknown

Atty. Dkt. No.: FHCC:010US

**CERTIFICATE OF MAILING
37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.

December 22, 2003

Date

Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

MS DD

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/FHCC:010US.

Applicants respectfully request that the listed documents be made of record in the present case.


Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: December 22, 2003



Form PTO-1449 (modified)

Atty. Docket No.
FHCC:010USSerial No.
10/648,978

List of Patents and Publications for Applicant's

Applicant
Thomas Spies
Veronika Spies

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
August 27, 2003Group:
1644U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 92/17198	3/27/92	PCT			
	B2	WO 01/71005	3/26/01	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Azuma <i>et al.</i> , "CD28 T lymphocytes-antigenic and functional properties," <i>J. Immunol.</i> , 150(4):1147-1159, 1993.
	C2	Bauer <i>et al.</i> , "Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA," <i>Science</i> , 285(5428):727-729, 1999.
	C3	Billadeau <i>et al.</i> , "NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway," <i>Nat. Immunol.</i> , 4(6):557-564, 2003.
	C4	Chalupny <i>et al.</i> , "ULBP4 is a novel ligand for human NKG2D," <i>Biochem. Biophys. Res. Commun.</i> , 305:129-135, 2003.
	C5	Cosman <i>et al.</i> , "ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor," <i>Immunity</i> , 14:123-133, 2001.
	C6	Das <i>et al.</i> , "MICA engagement by human Vgamma2Vdelta2 Tcells enhances their antigen-dependent effector function," <i>Immunity</i> , 15:83-93, 2001.
	C7	Diefenbach <i>et al.</i> , "Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages," <i>Nat. Immunol.</i> , 1:119-126, 2000.
	C8	Diefenbach <i>et al.</i> , "Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity," <i>Nature</i> , 413:165-171, 2001.

25348137.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Office of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

FHCC:010US

Serial No.

10/648,978

Applicant

Thomas Spies

Veronika Spies

Filing Date:

August 27, 2003

Group:

1644

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Groh <i>et al.</i> , "Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium," <i>Proc. Natl. Acad. Sci., USA</i> , 93:12445-12450, 1996.
	C10	Groh <i>et al.</i> , "Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells," <i>Nature Immunology</i> , 2(3):255-260, 2001.
	C11	Groh <i>et al.</i> , "Recognition of stress-induced MHC molecules by intestinal epithelial $\gamma\delta$ T cells," <i>Science</i> , 279:1737-1740, 1998.
	C12	Groh <i>et al.</i> , "Broad tumor-associated expression and recognition by tumor-derived $\gamma\delta$ T cells of MICA and MICB," <i>Proc. Natl. Acad. Sci., USA</i> , 96:6879-6884, 1999.
	C13	Groh <i>et al.</i> , "Tumour-derived soluble MIC ligand impair expression of NKG2D and T-cell activation," <i>Nature</i> , 419:734-738, 2002.
	C14	Houchins <i>et al.</i> , "DNA sequence analysis of NKG2, a family of related cDNA clones encoding typeII integral membrane proteins on human natural killer cells," <i>J. Exp. Med.</i> , 173:1017-1020, 1991.
	C15	Kubin <i>et al.</i> , "ULBP1, 2, 3: novel MHU class I-related molecules that bind to human cytomegalocirus glycoprotein UL16, activate NK cells," <i>European Journal of Immunology</i> , 31(5):1428-1437, 2001.
	C16	Li <i>et al.</i> , "Crystal structure of the MHC class I homolog MIC-A, a $\gamma\delta$ T cell ligand," <i>Immunity</i> , 10:577-584, 1999.
	C17	Pende <i>et al.</i> , "Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin," <i>Eur. J. Immunol.</i> , 31:1076-1086, 2001.
	C18	Posnett <i>et al.</i> , "Differentiation of human CD8 T cells: implications for in vivo persistence of CD8+ CD28- cytotoxic effector clones," <i>Int. Immunol.</i> , 11:229-241, 1999.
	C19	Roberts <i>et al.</i> , "NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment," <i>J. Immunol.</i> , 167:5527-5530, 2001.
	C20	Salih <i>et al.</i> , "Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia," 102(4):1389-96, <i>Blood</i> , 2003.

25348137.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

FHCC:010US

10/648,978

List of Patents and Publications for Applicant's

Applicant

Thomas Spies

Veronika Spies

INFORMATION DISCLOSURE STATEMENT

Filing Date:

August 27, 2003

Group:

1644

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C21	Sutherland <i>et al.</i> , "UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells," <i>J. Immunol.</i> , 168:671-679, 2002.
	C22	Wu <i>et al.</i> , "An activating immunoreceptor complex formed by NKG2D and DAP 10," <i>Science</i> , 285:730-732, 1999

25348137.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)